

Robert M Grant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2802593/publications.pdf>

Version: 2024-02-01

225
papers

23,671
citations

13099

68
h-index

8167

148
g-index

225
all docs

225
docs citations

225
times ranked

12040
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining information to estimate adherence in studies of pre-exposure prophylaxis for HIV prevention: Application to HPTN 067. <i>Statistics in Medicine</i> , 2022, , .	1.6	0
2	Characterizing HIV-Preventive, Plasma Tenofovir Concentrationsâ€”A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. <i>Clinical Infectious Diseases</i> , 2022, 75, 1873-1882.	5.8	10
3	Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2117-e2123.	5.8	33
4	Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2021, 72, 2025-2028.	5.8	4
5	Non-B variants of HIV-1 in San Francisco, California. <i>Infection, Genetics and Evolution</i> , 2021, 90, 104677.	2.3	0
6	Brief Report: Seroadaptive Behaviors Varied Among Geographically Diverse iPrEx Participants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, e43-e47.	2.1	2
7	Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 407-408.	1.1	1
8	Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, S27-S38.	2.1	24
9	Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067/ADAPT Study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 249-254.	1.2	25
10	Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 249-255.	5.8	7
11	HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health. <i>Aids</i> , 2020, 34, 699-706.	2.2	12
12	Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 239-254.	13.7	245
13	Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 149-152.	2.1	11
14	â€œA Good Habitâ€” Telehealth PrEP Users Find Benefit in Quarterly Monitoring Requirements. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595822091926.	1.5	12
15	Community pharmacy delivered PrEP to STOP HIV transmission: An opportunity NOT to miss!. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, e18-e24.	1.5	13
16	The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT. <i>AIDS and Behavior</i> , 2020, 24, 2178-2187.	2.7	13
17	Identification of hepatitis B virus genotype I in Thailand. <i>Journal of Medical Virology</i> , 2019, 91, 717-721.	5.0	4
18	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Increased uptake of early initiation of antiretroviral therapy and baseline drug resistance testing in San Francisco between 2001 and 2015. <i>PLoS ONE</i> , 2019, 14, e0213167.	2.5	4
20	Response to: Acceptability and Feasibility of a Pharmacist-Led HIV Pre-exposure Prophylaxis Program in the Midwestern United States. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz497.	0.9	4
21	HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012–2013. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, e18-e26.	2.1	10
22	Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, e94-e98.	2.1	13
23	Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 406-413.	2.1	11
24	Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 551-558.	2.1	24
25	Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 78-82.	2.1	18
26	Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 149-158.	2.1	12
27	Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 34-40.	2.1	5
28	Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. <i>Lancet HIV</i> , 2019, 6, e43-e50.	4.7	43
29	Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. <i>Aids</i> , 2019, 33, 867-872.	2.2	29
30	Skating on thin ice: stimulant use and suboptimal adherence to HIV pre-exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2018, 21, e25103.	3.0	53
31	A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. <i>AIDS Patient Care and STDs</i> , 2018, 32, 104-111.	2.5	68
32	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.	5.8	50
33	Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1712-1721.	5.8	48
34	In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?. <i>Aids</i> , 2018, 32, 809-818.	2.2	13
35	Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. <i>AIDS and Behavior</i> , 2018, 22, 3540-3549.	2.7	39
36	Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. <i>Journal of Clinical Virology</i> , 2018, 99-100, 67-70.	3.1	7

#	ARTICLE	IF	CITATIONS
37	The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. <i>Journal of Psychopharmacology</i> , 2018, 32, 779-792.	4.0	84
38	Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. <i>Lancet HIV</i> , 2018, 5, e68-e78.	4.7	96
39	HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 466-472.	1.2	4
40	Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study. <i>AIDS and Behavior</i> , 2018, 22, 1139-1149.	2.7	76
41	Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. <i>HIV Clinical Trials</i> , 2018, 19, 129-138.	2.0	51
42	Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy197.	0.9	12
43	“Losing the Phobia”: Understanding How HIV Pre-exposure Prophylaxis Facilitates Bridging the Serodivide Among Men Who Have Sex With Men. <i>Frontiers in Public Health</i> , 2018, 6, 250.	2.7	25
44	Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 169-174.	2.1	20
45	The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2018, 22, 3673-3680.	2.7	33
46	Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. <i>PLoS ONE</i> , 2018, 13, e0195764.	2.5	12
47	Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2018, 67, 962-964.	5.8	35
48	Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study. <i>Frontiers in Public Health</i> , 2018, 6, 151.	2.7	35
49	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. <i>PLoS ONE</i> , 2018, 13, e0190118.	2.5	18
50	Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. <i>AIDS and Behavior</i> , 2017, 21, 1361-1375.	2.7	109
51	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 778-783.	1.1	52
52	International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. <i>Sexually Transmitted Diseases</i> , 2017, 44, 306-309.	1.7	0
53	Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to <i>Treponema pallidum</i> ?. <i>Sexually Transmitted Infections</i> , 2017, 93, 313-313.	1.9	1
54	Risk, safety and sex among male PrEP users: time for a new understanding. <i>Culture, Health and Sexuality</i> , 2017, 19, 1301-1313.	1.8	75

#	ARTICLE	IF	CITATIONS
55	Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, 271-279.	2.1	40
56	Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. <i>Aids</i> , 2017, 31, 1709-1714.	2.2	103
57	Is pericoital or peri-insemination preexposure prophylaxis effective human immunodeficiency prevention for vaginal exposures?. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 230-231.	1.3	0
58	Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. <i>Lancet HIV</i> , 2017, 4, e331-e340.	4.7	187
59	Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. <i>AIDS and Behavior</i> , 2017, 21, 1325-1335.	2.7	151
60	Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, e104-e106.	2.1	64
61	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 177-182.	2.1	25
62	Recent advances in pre-exposure prophylaxis for HIV. <i>BMJ: British Medical Journal</i> , 2017, 359, j5011.	2.3	101
63	HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials. , 2017, , 479-498.		0
64	The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. <i>Journal of the International AIDS Society</i> , 2016, 19, 21105.	3.0	115
65	The Safety of Tenofovir+Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 281-286.	2.1	25
66	What people want from sex and preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 3-9.	3.8	66
67	Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, e115-e118.	2.1	29
68	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 184-188.	2.1	1
69	HIV moments and pre-exposure prophylaxis. <i>Lancet, The</i> , 2016, 387, 1507-1508.	13.7	11
70	PrEP adherence among trans women in Brazil—access needed for this key population — Authors' reply. <i>Lancet HIV</i> , 2016, 3, e200-e201.	4.7	1
71	Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. <i>Aids</i> , 2016, 30, 1973-1983.	2.2	721
72	The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. <i>AIDS and Behavior</i> , 2016, 20, 1527-1534.	2.7	41

#	ARTICLE	IF	CITATIONS
73	Pharmacology supports on-demand PrEP. <i>Lancet HIV,the</i> , 2016, 3, e405-e406.	4.7	17
74	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV,the</i> , 2016, 3, e521-e528.	4.7	66
75	Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6692-6697.	3.2	59
76	HIV Serodisclosure and Sexual Behavior During International Travel. <i>Sexually Transmitted Diseases</i> , 2016, 43, 459-464.	1.7	9
77	Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S226-S229.	2.1	33
78	Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. <i>AIDS and Behavior</i> , 2016, 20, 1535-1540.	2.7	33
79	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.	5.8	40
80	Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. <i>JAMA Internal Medicine</i> , 2016, 176, 75.	5.1	535
81	Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). <i>AIDS and Behavior</i> , 2016, 20, 1478-1488.	2.7	38
82	Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+T-Cell Activation. <i>Journal of Infectious Diseases</i> , 2016, 213, 569-573.	4.0	11
83	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 606-609.	2.1	9
84	Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. <i>Journal of the International AIDS Society</i> , 2015, 18, 19980.	3.0	53
85	Transactional sex and prevalence of STIs: a cross-sectional study of MSM and transwomen screened for an HIV prevention trial. <i>International Journal of STD and AIDS</i> , 2015, 26, 879-886.	1.1	29
86	HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. <i>Lancet HIV,the</i> , 2015, 2, e512-e519.	4.7	225
87	<i>Editorial Commentary</i> : Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2015, 61, 1604-1605.	5.8	15
88	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 572-580.	5.8	132
89	The FACTS about women and pre-exposure prophylaxis. <i>Lancet HIV,the</i> , 2015, 2, e228.	4.7	3
90	Ending Sexual HIV Transmission: Lessons Learned from Perinatal HIV. <i>Journal of the Association of Nurses in AIDS Care</i> , 2015, 26, 520-525.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406.	4.0	62
92	Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8379-8384.	7.1	14
93	Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 211, 1202-4.	4.0	15
94	Streamlining HIV Testing for HIV Preexposure Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 179-183.	3.9	10
95	Gay and bisexual men engage in fewer risky sexual behaviors while traveling internationally: a cross-sectional study in San Francisco. <i>Sexually Transmitted Infections</i> , 2015, 91, 220-225.	1.9	16
96	Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. <i>Aids</i> , 2015, 29, 331-337.	2.2	37
97	Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 1199-1204.	1.2	27
98	Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv126.	0.9	9
99	Reply to Boyd et al. <i>Clinical Infectious Diseases</i> , 2015, 60, 327-327.	5.8	0
100	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). <i>PLoS ONE</i> , 2014, 9, e83736.	2.5	125
101	HIV-1 Drug Resistance in Preexposure Prophylaxis Trials. , 2014, , 1-18.		0
102	Helping our patients take <scp>HIV</scp> preâ€œexposure prophylaxis (<scp>PrEP</scp>): a systematic review of adherence interventions. <i>HIV Medicine</i> , 2014, 15, 385-395.	2.2	52
103	Regulatory Considerations for Antiretroviral Prophylaxis to Prevent HIV Acquisition. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 153-155.	4.7	2
104	Integrated Next Step Counseling for Sexual Health Promotion and Medication Adherence for Individuals Using Pre-exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A159-A159.	1.1	4
105	Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1020-1026.	5.8	132
106	Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 528-537.	2.1	63
107	Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 530-537.	2.1	73
108	HIV Prevention in Clinical Care Settings. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 390.	7.4	109

#	ARTICLE	IF	CITATIONS
109	HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 468-475.	9.1	128
110	Reasons Boston MSM Enrolled in Placebo Controlled PrEP Trials Did Not Continue Using PrEP When it Was Available in an Open Label Study. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A28-A29.	1.1	0
111	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829.	9.1	1,039
112	HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1217-1227.	4.0	68
113	Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. <i>Aids</i> , 2014, 28, 851-859.	2.2	123
114	Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men. <i>PLoS ONE</i> , 2014, 9, e91513.	2.5	27
115	Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24Gag. <i>Bio-protocol</i> , 2014, 4, .	0.4	8
116	Use of Antiretrovirals for HIV Prevention: What Do We Know and What Donâ€™t We Know?. <i>Current HIV/AIDS Reports</i> , 2013, 10, 142-151.	3.1	60
117	Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 961-967.	1.2	91
118	Participant Experiences and Facilitators and Barriers to Pill Use Among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco. <i>AIDS Patient Care and STDs</i> , 2013, 27, 560-566.	2.5	76
119	Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 79-86.	2.1	158
120	Changes in Seroadaptive Practices from before to after Diagnosis of Recent HIV Infection among Men Who Have Sex with Men. <i>PLoS ONE</i> , 2013, 8, e55397.	2.5	33
121	No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. <i>PLoS ONE</i> , 2013, 8, e81997.	2.5	193
122	Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. <i>Science Translational Medicine</i> , 2012, 4, 151ra125.	12.4	807
123	The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. <i>PLoS Medicine</i> , 2012, 9, e1001323.	8.4	76
124	Preexposure Prophylaxis for HIV Infection among African Women. <i>New England Journal of Medicine</i> , 2012, 367, 411-422.	27.0	1,377
125	Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment. <i>AIDS and Behavior</i> , 2012, 16, 1243-1259.	2.7	71
126	Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco. <i>PLoS ONE</i> , 2011, 6, e23688.	2.5	144

#	ARTICLE	IF	CITATIONS
127	Sentinel Surveillance of HIV-1 Transmitted Drug Resistance, Acute Infection and Recent Infection. PLoS ONE, 2011, 6, e25281.	2.5	41
128	Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. Journal of Antimicrobial Chemotherapy, 2011, 66, 240-250.	3.0	159
129	Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes. Journal of Infectious Diseases, 2011, 203, 1174-1181.	4.0	125
130	HIV RNA level in early infection is predicted by viral load in the transmission source. Aids, 2010, 24, 941-945.	2.2	65
131	Sexual risk behaviours and HIV-1 prevalence among urban men who have sex with men in Cape Town, South Africa. Sexual Health, 2010, 7, 149.	0.9	53
132	Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. PLoS ONE, 2010, 5, e15510.	2.5	64
133	Antiretroviral Agents Used by HIV-Uninfected Persons for Prevention: Pre- and Postexposure Prophylaxis. Clinical Infectious Diseases, 2010, 50, S96-S101.	5.8	48
134	Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine, 2010, 363, 2587-2599.	27.0	4,268
135	Sexual Seroadaptation: Lessons for Prevention and Sex Research from a Cohort of HIV-Positive Men Who Have Sex with Men. PLoS ONE, 2010, 5, e8831.	2.5	42
136	Frequent International Travel by Men Who Have Sex With Men Recently Diagnosed With HIV-1: Potential for Transmission of Primary HIV-1 Drug Resistance: Table 1. Journal of Travel Medicine, 2008, 15, 454-456.	3.0	18
137	Potentially Exposed but Uninfected Individuals Produce Cytotoxic and Polyfunctional Human Immunodeficiency Virus Type 1-Specific CD8 ⁺ T-Cell Responses Which Can Be Defined to the Epitope Level. Vaccine Journal, 2008, 15, 1745-1748.	3.1	30
138	Whither or Wither Microbicides?. Science, 2008, 321, 532-534.	12.6	126
139	Immunity to HIV-1 Is Influenced by Continued Natural Exposure to Exogenous Virus. PLoS Pathogens, 2008, 4, e1000185.	4.7	14
140	Distinct Patterns of Cytokine Regulation of APOBEC3G Expression and Activity in Primary Lymphocytes, Macrophages, and Dendritic Cells. Journal of Biological Chemistry, 2007, 282, 3539-3546.	3.4	134
141	Target Cell APOBEC3C Can Induce Limited G-to-A Mutation in HIV-1. PLoS Pathogens, 2007, 3, e153.	4.7	51
142	Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. PLOS Clinical Trials, 2007, 2, e27.	3.5	233
143	Reply to McGovern. Clinical Infectious Diseases, 2007, 44, 1013-1013.	5.8	0
144	Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. Aids, 2007, 21, 239-241.	2.2	46

#	ARTICLE	IF	CITATIONS
145	Dehydroepiandrosterone (DHEA) Effects on HIV Replication and Host Immunity: A Randomized Placebo-Controlled Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 77-85.	1.1	25
146	Research in situ. <i>Nature Methods</i> , 2007, 4, 887-890.	19.0	4
147	HIV Drug-resistant Strains as Epidemiologic Sentinels. <i>Emerging Infectious Diseases</i> , 2006, 12, 191-197.	4.3	13
148	Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. <i>Aids</i> , 2006, 20, 2123-2125.	2.2	42
149	Linking HIV and Antiretroviral Drug Resistance Surveillance in Peru. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 501-505.	2.1	47
150	Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. <i>Aids</i> , 2006, 20, 2193-2197.	2.2	66
151	HIV-1-Specific CD4+ T Cell Responses in Chronically HIV-1 Infected Blippers on Antiretroviral Therapy in Relation to Viral Replication Following Treatment Interruption. <i>Journal of Clinical Immunology</i> , 2006, 26, 40-54.	3.8	19
152	Genotypic Resistance and Immunologic Outcomes Among HIV-1-Infected Women With Viral Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 68-74.	2.1	10
153	The Cost of Access to HIV Treatment. <i>Science</i> , 2006, 314, 1540-1541.	12.6	0
154	Chemoprophylaxis of HIV Infection: Moving Forward with Caution. <i>Journal of Infectious Diseases</i> , 2006, 194, 874-876.	4.0	19
155	HIV/AIDS: Antiretroviral Therapy for Hepatitis B Virusâ€“HIVâ€“Coinfected Patients: Promises and Pitfalls. <i>Clinical Infectious Diseases</i> , 2006, 43, 904-910.	5.8	67
156	Preexposure Prophylaxis for HIV. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 863.	7.4	66
157	Human Immunodeficiency Virus Type 1 Vpr Induces DNA Replication Stress In Vitro and In Vivo. <i>Journal of Virology</i> , 2006, 80, 10407-10418.	3.4	91
158	Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting?. <i>Sexually Transmitted Infections</i> , 2006, 82, 461-466.	1.9	196
159	T-Cell Activation and Memory Phenotypes in Cerebrospinal Fluid During HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 16-22.	2.1	29
160	High-Risk Sexual Behavior in Adults With Genotypically Proven Antiretroviral-Resistant HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 463-471.	2.1	36
161	Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. <i>Aids</i> , 2005, 19, 1351-1359.	2.2	16
162	A decrease in drug resistance levels of the HIV epidemic can be bad news. <i>Bulletin of Mathematical Biology</i> , 2005, 67, 761-782.	1.9	13

#	ARTICLE	IF	CITATIONS
163	The role of viral fitness in HIV pathogenesis. <i>Current HIV/AIDS Reports</i> , 2005, 2, 29-34.	3.1	16
164	AIDS: Promote HIV Chemoprophylaxis Research, Don't Prevent It. <i>Science</i> , 2005, 309, 2170-2171.	12.6	67
165	Resistance Testing in Drug-Naive HIV-Infected Patients: Is it Time?. <i>Clinical Infectious Diseases</i> , 2005, 41, 1324-1325.	5.8	35
166	Detection of Acute HIV Infections. <i>New England Journal of Medicine</i> , 2005, 353, 631-633.	27.0	32
167	Interruption of Treatment with Individual Therapeutic Drug Classes in Adults with Multidrug-Resistant HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2005, 192, 1537-1544.	4.0	146
168	Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV. <i>Clinical Infectious Diseases</i> , 2005, 41, 1507-1513.	5.8	134
169	Higher CD4+T Cell Counts Associated with Low Viral Replication Capacity among Treatment-Naive Adults in Early HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2004, 190, 251-256.	4.0	74
170	Human Immunodeficiency Virus Type 1 Superinfection Was Not Detected following 215 Years of Injection Drug User Exposure. <i>Journal of Virology</i> , 2004, 78, 94-103.	3.4	75
171	Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. <i>Aids</i> , 2004, 18, 81-88.	2.2	244
172	HIV-1 superinfection and viral diversity. <i>Aids</i> , 2004, 18, 1513-1520.	2.2	29
173	Virological evaluation of the "Ottawa case"™ indicates no evidence for HIV-1 superinfection. <i>Aids</i> , 2004, 18, 331-334.	2.2	9
174	Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection. <i>PLoS Medicine</i> , 2004, 1, e64.	8.4	67
175	The clinical implications of reduced viral fitness. <i>Current Infectious Disease Reports</i> , 2004, 6, 151-158.	3.0	9
176	Relating HIV-1 Sequence Variation to Replication Capacity via Trees and Forests. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2004, 3, 1-18.	0.6	35
177	Persistence of primary drug resistance among recently HIV-1 infected adults. <i>Aids</i> , 2004, 18, 1683-1689.	2.2	139
178	HIV-Producing T Cells in Cerebrospinal Fluid. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1237-1244.	2.1	13
179	Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. <i>Transfusion</i> , 2003, 43, 451-458.	1.6	11
180	Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1594-1599.	3.9	71

#	ARTICLE	IF	CITATIONS
181	Accuracy of the TRUGENE HIV-1 Genotyping Kit. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1586-1593.	3.9	111
182	Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. <i>Aids</i> , 2003, 17, 2337-2343.	2.2	23
183	Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. <i>Aids</i> , 2003, 17, 361-370.	2.2	80
184	High levels of adherence do not prevent accumulation of HIV drug resistance mutations. <i>Aids</i> , 2003, 17, 1925-1932.	2.2	200
185	Increased Human T-Lymphotropic Virus Type II Proviral Load Following Highly Active Retroviral Therapy in HIV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 655-656.	2.1	18
186	Dual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene. <i>Journal of Virology</i> , 2003, 77, 6743-6752.	3.4	46
187	Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays. <i>Aids</i> , 2003, 17, 629-631.	2.2	9
188	Drug resistance mutations in HIV-1. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2003, 11, 92-6.	2.9	35
189	Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults. <i>Journal of Virology</i> , 2002, 76, 11104-11112.	3.4	151
190	Selective Loss of Innate CD4+ α 24 Natural Killer T Cells in Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2002, 76, 7528-7534.	3.4	152
191	Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 181.	7.4	416
192	Progress Toward a Human CD4/CCR5 Transgenic Rat Model for De Novo Infection by Human Immunodeficiency Virus Type 1. <i>Journal of Experimental Medicine</i> , 2002, 195, 719-736.	8.5	97
193	CD4+T Cell Kinetics and Activation in Human Immunodeficiency Virus-Infected Patients Who Remain Viremic Despite Long-Term Treatment with Protease Inhibitor-Based Therapy. <i>Journal of Infectious Diseases</i> , 2002, 185, 315-323.	4.0	103
194	HIV-Related Neuropathology, 1985 to 1999: Rising Prevalence of HIV Encephalopathy in the Era of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 171-177.	2.1	206
195	Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. <i>Aids</i> , 2002, 16, 1103-1111.	2.2	140
196	Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. <i>Aids</i> , 2002, 16, 201-207.	2.2	150
197	Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. <i>Aids</i> , 2002, 16, 2342-2344.	2.2	47
198	Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia. <i>New England Journal of Medicine</i> , 2001, 344, 472-480.	27.0	672

#	ARTICLE	IF	CITATIONS
199	Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes. <i>Aids</i> , 2001, 15, 179-184.	2.2	11
200	Cerebrospinal fluid response to structured treatment interruption after virological failure. <i>Aids</i> , 2001, 15, 1251-1259.	2.2	59
201	Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. <i>Nature Medicine</i> , 2001, 7, 73-79.	30.7	498
202	Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. <i>Nature Medicine</i> , 2001, 7, 712-718.	30.7	141
203	Primary and Recombinant HIV Type 1 Strains Resistant to Protease Inhibitors Are Pathogenic in Mature Human Lymphoid Tissues. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 517-523.	1.1	20
204	Postexposure Prophylaxis for Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: Identification and Characterization of the Source of Exposure. <i>Journal of Infectious Diseases</i> , 2001, 184, 1608-1612.	4.0	28
205	Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. <i>Aids</i> , 2000, 14, 2877-2887.	2.2	49
206	Reversal of Human Immunodeficiency Virus Type 1-Associated Hematosuppression by Effective Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2000, 30, 504-510.	5.8	57
207	Cytopathicity of Human Immunodeficiency Virus Type 2 (HIV-2) in Human Lymphoid Tissue Is Coreceptor Dependent and Comparable to That of HIV-1. <i>Journal of Virology</i> , 2000, 74, 9594-9600.	3.4	54
208	A Tale of Two Futures: HIV and Antiretroviral Therapy in San Francisco. <i>Science</i> , 2000, 287, 650-654.	12.6	349
209	HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. <i>Aids</i> , 1999, 13, F35-F43.	2.2	382
210	Short Communication Antibody and Cellular Immune Responses in Breakthrough Infection Subjects after HIV Type 1 Glycoprotein 120 Vaccination. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1685-1689.	1.1	25
211	Evolution of viral quasispecies in interferon-treated patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 1999, 31, 618-627.	3.7	11
212	Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. <i>Aids</i> , 1999, 13, 1051-1061.	2.2	118
213	Not all is dead in HIV-1 graveyard. <i>Lancet, The</i> , 1998, 351, 308-309.	13.7	6
214	Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors. <i>New England Journal of Medicine</i> , 1998, 339, 307-311.	27.0	456
215	Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. <i>Aids</i> , 1998, 12, F97-F102.	2.2	90
216	Diverse Host Responses and Outcomes following Simian Immunodeficiency Virus SIVmac239 Infection in Sooty Mangabeys and Rhesus Macaques. <i>Journal of Virology</i> , 1998, 72, 9597-9611.	3.4	138

#	ARTICLE	IF	CITATIONS
217	High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection.. Journal of Clinical Investigation, 1998, 101, 2301-2308.	8.2	245
218	HIV replication and pathogenesis. Current Opinion in Infectious Diseases, 1996, 9, 7-13.	3.1	2
219	Frequent Presence of a Novel Herpesvirus Genome in Lesions of Human Immunodeficiency Virus-Negative Kaposi's Sarcoma. Journal of Infectious Diseases, 1996, 173, 248-251.	4.0	83
220	The High Prevalence of Genital Herpes Among Patients With Genital Ulcer Disease in Uganda. Sexually Transmitted Diseases, 1995, 22, 351-354.	1.7	32
221	Activation of virus replication after vaccination of HIV-1-infected individuals.. Journal of Experimental Medicine, 1995, 182, 1727-1737.	8.5	332
222	Early Christian Geography. Vigiliae Christianae, 1992, 46, 105-111.	0.1	3
223	Acyclovir-Resistant Herpes Simplex Virus Infections in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1989, 320, 293-296.	27.0	470
224	Five Apologists and Marcus Aurelius. Vigiliae Christianae, 1988, 42, 1-17.	0.1	41
225	The Apostolic Fathers' First Thousand Years. Church History, 1988, 57, 20-28.	0.0	0